Sundar Jagannath

4 ta ish

Icahn School of Medicine at Mount Sinai

1. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

   Noopur Raje, Jesús G. Berdeja, Yi Lin +20

   MaqolaOAOchiq kirish20195 iqtibos

   ABIABI:AkademIndex/2026.other.082848

2. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

   Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani +33

   Maqola20214 iqtibos

   ABIABI:AkademIndex/2026.other.475845

3. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

   S. Vincent Rajkumar, Meletios Α. Dimopoulos, Antonio Palumbo +31

   Maqola20143 iqtibos

   ABIABI:AkademIndex/2026.other.466311

4. International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

   Hervé Avet‐Loiseau, Faith E. Davies, Mehmet Samur +43

   Maqola20252 iqtibos

   ABIABI:AkademIndex/2026.other.480252